Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation

Area of Science:

• Hematology
• Oncology
• Coagulation Science

Background:

• Disseminated intravascular coagulation (DIC) is a severe complication in acute nonlymphoid leukemia (ANLL).
• Tissue factor (TF) is a key initiator of the coagulation cascade and is expressed by various cells, including leukemia cells.

Purpose of the Study:

• To investigate the correlation between tissue factor activity (TFA) of leukemia cells and the incidence of DIC in ANLL patients.
• To evaluate the role of TFA in guiding heparin therapy for DIC in ANLL.

Main Methods:

• Measurement of TFA in 10^8 leukemia cells from 82 ANLL patients using a clotting method.
• Clinical data analysis, including DIC development and heparin treatment response.
• Retrospective analysis of clinical features and correlation with TFA levels.

Main Results:

• Significantly higher mean TFA (8.3 U) in ANLL patients with DIC compared to those without DIC (0.3 U).
• Markedly elevated mean TFA in M3 subtype leukemia (37.2 U) versus non-M3 subtypes (0.9 U), with some non-M3 cases also showing high TFA and DIC.
• Heparin dosage for DIC treatment was effectively controlled by TFA levels, with a formula derived for adequate dosage (97000X + 9000 units/day).

Conclusions:

• Leukemia cell TFA is a significant predictor of DIC development in ANLL.
• TFA measurement provides a valuable tool for monitoring and guiding heparin therapy in ANLL-associated DIC.
• Tailoring heparin dosage based on TFA levels ensures effective management of DIC in leukemia patients.